Cerebrospinal fluid and behavioral changes after methyltestosterone administration: Preliminary findings

Archives of General Psychiatry

Volumn 58, Issue 2, 2001, Pages 172-177

  Daly, R C ^a   Su, T P ^a   Schmidt, P J ^a   Pickar, D ^a   Murphy, D L ^a   Rubinow, D R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLTESTOSTERONE;

ARTICLE; BEHAVIOR; CEREBROSPINAL FLUID ANALYSIS; DOPING; DRUG ABUSE; HUMAN; RATING SCALE;

EID: 0035133020     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.58.2.172     Document Type: Article

References (40)

1. Affective and psychotic symptoms associated with anabolic steroid use
2. Selected psychological characteristics of anabolic-androgenic steroid users
3. Psychiatric and medical effects of anabolic-androgenic steroid use: A controlled study of 160 athletes
4. Neuropsychiatric effects of anabolic steroids in male normal volunteers
5. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial
6. Psychosexual effects of three doses of testosterone cycling in normal men
7. Anabolic androgenic steroids increase beta-endorphin levels in the ventral tegmental area in the male rat brain
8. Chronic anabolic-androgenic steroid treatment during adolescence increases anterior hypothalamic vasopressin and aggression in intact hamsters
9. Regulation of glucocorticoid receptor immunoreactivity in the rat hippocampus by androgenic-anabolic steroids
10. Direct effects of the anabolic/androgenic steroids, stanozolol and 17 alpha-methyltestosterone, on benzodiazepine binding to the gamma-aminobutyric acid(a) receptor
11. Reversal of testosterone-induced dominance by the serotonergic agonist quipazine
12. Serotonergic control of androgen-induced dominance
13. Symptoms and correlates of anabolic-androgenic steroid dependence
14. Cerebrospinal fluid somatostatin and psychiatric illness
15. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients
16. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans
17. A diagnostic interview: The schedule for affective disorders and schizophrenia
18. The validity and reliability of the visual analogue mood scale
19. Rapid radioimmunoassay for corticotropin in unextracted human plasma
20. Corticotropin-releasing factor: Pharmacokinetics in man
21. The thymus-adrenal connection: Thymosin has corticotropin-releasing activity in primates
22. The neuroendocrine effects of interleukin-2 treatment
23. The relationship of saline-induced changes in vasopressin secretion to basal and corticotropin-releasing hormone-stimulated adrenocorticotropin and cortisol secretion in man
24. Determination of free methyltestosterone in plasma samples
25. Somatostatin
26. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: Potential clinical implications
27. Application of a novel cation-exchange reagent, Igepon T-77 (N-methyl oleoyl taurate), to microbore separations of alumina extracts of catecholamines from cerebrospinal fluid, plasma, urine and brain tissue with amperometric detection
28. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection
29. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression
30. Lack of effect of various endocrine manipulations on tryptophan hydroxylase activity of individual nuclei of the hypothalamus, limbic system, and midbrain of the rat
31. CSF monoamine metabolites in mania
32. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients
33. Lumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes
34. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine
35. Central serotonin activity and aggression: Inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects
36. Serotonin function in human subjects: Intercorrelations among central 5-HT indices and aggressiveness
37. CSF metabolites in borderline personality disorder compared with normal controls
38. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder
39. Aggression and personality: Association with amino acids and monoamine metabolites
40. Anabolic-androgenic steroid abuse and psychopathology